TABLE 2:

Incidence of LE in patients with ALL treated with intrathecal and IV MTX

Study	Modality	Prevalence of LE^*	Point in Therapy
Wilson et al, 1991¹⁵	MR imaging	0/21 (0)	Baseline
Chu et al, 2003¹⁴	MR imaging	0/17 (0)	Baseline
Asato et al, 1992¹⁶	MR imaging	6/16 (38)	End Induction
Chu et al, 2003¹⁴	MR imaging	0/20 (0)	8 wk after diagnosis
Wilson et al, 1991¹⁵	MR imaging	0/23 (0)	Beginning of consolidation
Chu et al, 2003¹⁴	MR imaging	4/19 (21)	20 wk after diagnosis
Wilson et al, 1991¹⁵	MR imaging	15/25 (60)	Middle of consolidation
Paakko et al, 1996¹⁰	MR imaging	2/6 (33)	End of consolidation
Wilson et al, 1991¹⁵	MR imaging	15/25 (60)	Begin of maintenance
Ochs et al, 1983⁵	CT	10/53 (19)	Continuation
Paakko et al, 2000¹²	MR imaging	3/17 (18)	During therapy
Wilson et al, 1991¹⁵	MR imaging	12/23 (52)	1 year after diagnosis
Mahoney et al, 1998¹⁸	CT, MR imaging	57/75 (76)	1 year after diagnosis
Chu et al, 2003¹⁴	MR imaging	1/19 (5)	1 year after therapy
Chu et al, 2003¹⁴	MR imaging	1/17 (6)	2 y after therapy
Paakko et al, 1992⁸	MR imaging	1/11 (9)	3 y after therapy
Chu et al, 2003¹⁴	MR imaging	2/16 (13)	3 y after therapy
Bakke et al, 1993¹⁷	MR imaging	8/15 (53)	5 y after therapy
Ochs et al, 1991⁷	CT	7/25 (28)	6 y after therapy
Hertzberg et al, 1997¹¹	CT, MR imaging	15/39 (39)	7 y after therapy
Kingma et al, 2001¹³	MR imaging	6/16 (38)	10 y after diagnosis